
Remember when Bloomberg literally ran the headline: "China's curing cancer faster and cheaper than anywhere else. But some worry they may be going too fast"? Now look at how the Financial Times is framing this new FDA decision: "FDA rejects cancer drug invented in China in blow to Beijing's biotech sector." A "blow to Beijing"? Chinese lung cancer patients ALREADY have this drug. Not only is it approved across China, it is covered by public health insurance, where a single vial costs roughly $100 USD (around $1,300 per treatment cycle before insurance even kicks in to cover most of the bill). Meanwhile, in separate head-to-head trials, this exact Chinese drug beat Merck's Keytruda, which is Big Pharma's $30 billion-a-year cash cow and the best-selling cancer drug on earth. In the U.S., Keytruda carries a list price of over $12,500 per three-week dose, adding up to more than $200,000 a year. So why did the FDA block this initial U.S. application? While a larger global trial is still wrapping up, the U.S. partner company applied first to use the drug for a smaller, harder-to-treat group of lung cancer patients whose previous treatments had failed. Even though the drug clearly slowed down tumor growth, the FDA rejected it, claiming that slowing tumors wasn't enough without stronger long-term survival proof and complaining that too many patients in the trial were Chinese. Here is the kicker: a Harvard Medical School study found that over half (57%) of the cancer drugs fast-tracked onto the market by the FDA failed to prove within five years that they actually helped patients live longer or feel better. For years, the FDA happily let Western pharma giants charge Americans $200,000 a year for drugs that only slowed or shrank tumors on paper. Yet the moment a superior Chinese drug threatens Big Pharma's biggest monopoly and exposes what cancer treatment actually costs outside the U.S. pricing racket, the FDA suddenly discovers "strict standards." Even if you take the FDA's red tape at face value, look at the media sickness on display. Western outlets are cheering a blocked lung cancer treatment like it is a geopolitical scoreboard win over China, when the only people being denied the option right now are Americans. Imagine framing American cancer patients having fewer options while still paying $200,000 a year as "owning Beijing."
FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector ft.trib.al/RfC5vXI



























